quarters. Domestic formulation growth was at 10.5%. EBITDA margins saw 460bps expansion to 24.6% (higher than estimated 21.4%) on better business mix. There was 150bps/160bps margin surprise in materials/other expenses. Core PAT (adjusted for forex...